-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
pembrolizumab
-
Oncology Trials Could Benefit From Increased Data on Tobacco Use
By Leah Lawrence Posted: June 24, 2020 As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially and during the study, should be a required data element for all prospective clinical studies and that these studies should consider designs that could also determine the most effective…
-
Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis
By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in nonsquamous NSCLC. Although prior research has shown that these mutations are tied to poor outcomes in patients treated with immune checkpoint blockade, particularly in the…
-
-
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field of lung cancer research. Treatment progress gained momentum and finally reached a tipping point in the mid-2010s, with the number of advances over the last…
-
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are now available in routine clinical practice for the treatment of patients with advanced or metastatic NSCLC and SCLC. Several biomarkers have been reported to predict…
-
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. By Valérie Gounant, MD, and Elisabeth Quoix, MD, PhD Posted: February 12, 2020 Dr. Valérie Gounant Prof. Elisabeth Quoix The advent of…
-
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518-2527. Immune checkpoint inhibition is now part of routine care for patients with…
-
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. Greg Durm, MD, is a medical oncologist at the Indiana University Simon Cancer Center and principal investigator of a phase II trial examining concurrent chemoradiation…
-
2019 IASLC World Conference on Lung Cancer Updates
Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of thoracic oncology patient care, the conference offered attendees from all specialties an opportunity to learn about novel research and hear from the field’s top experts.…
View ILCN Archives
Provider Resources
Popular Articles